Alex Carchidi is a writer, consultant, and entrepreneur, with a focus on financial and investment topics. He is a contributor to The Motley Fool, where he provides analysis and insights on various stocks and investment opportunities. His work has also been featured in Yahoo News, Yahoo Finance, Cigalah Group, and Nasdaq.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Alex Carchidi's coverage predominantly focuses on investment analysis within the healthcare and pharmaceutical sectors, particularly gene-editing companies and biotech stocks. His articles often cite data to support his analyses.
To effectively engage Alex, provide pitches that offer in-depth insights into investment opportunities or risks within the healthcare and pharmaceutical industries. Experts with a deep understanding of gene-editing technologies, biotech stocks, and pharmaceutical companies may find success by offering valuable perspectives for inclusion in his articles.
Given that Alex does not have a specific geographic focus mentioned, sources from any location who possess relevant expertise in these areas could potentially be suitable for engagement.
This information evolves through artificial intelligence and human feedback. Improve this profile .
A recovery plan is underway, but it isn't a slam dunk.
By: Alex Carchidi
Key Points Walgreens Boots Alliance is planning to scale down its operations. Its major growth campaign looks to be stalled, at least for now. There isn't yet a coherent plan for change, but one may emerge soon. Motley Fool Issues Rare “All In” Buy Alert
This business is turning over a new leaf, but it still isn't flourishing.
By: Alex Carchidi
Key Points Eli Lilly and Novo Nordisk will need to share the weight-loss drugs market someday. Altimmune's candidate looks like it could succeed where their medicines struggle. Terns Pharmaceuticals has plenty of cash, but that's not the only thing it needs. Motley Fool Issues Rare “All In” Buy Alert
By: Alex Carchidi
Key Points Pfizer doesn't currently produce any anti-obesity medicines, but it wants to do so. However, its most mature program on that front isn't exactly a sizzler. It's also far behind the market's leaders in terms of its progress. Motley Fool Issues Rare “All In” Buy Alert
Key Points Pfizer and Roche don't have any anti-obesity medicines marketed yet. Both are trying to change that as fast as possible. Having a lot of cash on hand could shake things up quite easily.
By: Alex Carchidi
Eli Lilly is still a smart pick, but these two stocks could grow more in the near term.
By: Alex Carchidi
Key Points Roche's latest data update indicates one of its weight-loss programs is doing well. It has more than enough resources to bring its candidate to the market. There's still a handful of additional clinical trials for its program to get through.
Eli Lilly is still a smart pick, but these two stocks could grow more in the near term.
Managing your psychology is key to building wealth via buying the dip.
(833) 317-6278 
